Trial Profile

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN CD70A (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Renal cell carcinoma
Focus Adverse reactions; First in man
Sponsors Seagen

Most Recent Events

09 Jan 2019 Results (n=18) published in the Cancer.
22 Aug 2018 Results (n=20) published in the Investigational New Drugs.
22 Aug 2018 Status changed from discontinued to completed, according to results published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com